Filing Flows › Comparisons › KRRO vs ENSC
Korro Bio vs Ensysce Biosciences: KRRO and ENSC compared
Korro Bio is the larger company: $1.3M of revenue in its latest quarter (Q4 2025) against $1.2M for Ensysce Biosciences (Q2 2026). Ensysce Biosciences is growing faster (-15% against -43% a year earlier).
Where the money goes: KRRO and ENSC
Korro Bio (KRRO) · Q4 2025
Korro Bio, Q4 2025: revenue $1.3M (-43% year over year), net loss $50.0M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
Ensysce Biosciences (ENSC) · Q2 2026
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Korro Bio (KRRO) | Ensysce Biosciences (ENSC) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $1.3M | $1.2M |
| Revenue growth, Y/Y | -43% | -15% |
| Operating margin | n/m | -221.3% |
| Net earnings | −$50.0M | −$2.6M |
| Net margin | — | -220.8% |
| Operating cash flow | −$17.7M | −$2.0M |
Questions
Which is bigger, Korro Bio or Ensysce Biosciences?
Korro Bio is the larger company: $1.3M of revenue in its latest quarter (Q4 2025) against $1.2M for Ensysce Biosciences (Q2 2026).
Is Korro Bio or Ensysce Biosciences growing faster?
Ensysce Biosciences is growing faster (-15% against -43% a year earlier).
More: Korro Bio earnings · how Korro Bio makes money · Ensysce Biosciences earnings · how Ensysce Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 12, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.